Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3207_Библиотеки_им_академика_М_И_Перельмана.pdf
4 Overview of the Comorbidity … 99
shift. Diabetes and Vascular Disease Research. 2019;16(2):118–127. https://
doi.org/10.1177/1479164119827611.
12. Sperling LS, Mechanick JI, Neeland IJ, et al. The cardiometabolic health
alliance: Working toward a new care model for the metabolic syndrome.
Journal of the American College of Cardiology. 2015;66(9):1050–1067.
https://doi.org/10.1016/j.jacc.2015.06.1328.
13. Cornier MA, Dabelea D, Hernandez TL, et al. The metabolic syndrome.
EndocrineReviews. 2008;29(7):777–822.https://doi.org/10.1210/er.2008-
0024.
14. Lim SS, Kakoly NS, Tan JWJ, et al. Metabolic syndrome in polycystic ovary
syndrome: A systematic review, meta-analysis and meta-regression. Obesity
Reviews. 2018;20(2):339–352. https://doi.org/10.1111/obr.12762.
15. Farrell GC, Haczeyni F, Chitturi S. Pathogenesis of NASH: How
metabolic complications of overnutrition favour lipotoxicity and pro-
inflammatory fatty liver disease. Advances in Experimental Medicine and
Biology. 2018;1061:19–44. https://doi.org/10.1007/978-981-10-8684-7_
3.
16. Kazemi M, Pierson RA, Lujan ME, et al. Comprehensive evaluation of
type 2 diabetes and cardiovascular disease risk profiles in reproductive-age
women with polycystic ovary syndrome: A large Canadian cohort. Journal
of Obstetrics and Gynaecology Canada. In press. https://doi.org/10.1016/j.
jogc.2018.11.026.
17. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resis-
tance: Insulin hypersecretion and specific association with the insulin
resistance syndrome. Hepatology. 2002;35(2):373–379. https://doi.org/10.
1053/jhep.2002.30692.
18. Drager LF, Togeiro SM, Polotsky VY, Lorenzi-Filho G. Obstructive sleep
apnea: A cardiometabolic risk in obesity and the metabolic syndrome. Jour-
nal of the American College of Cardiology. 2013;62(7):569–576. https://doi.
org/10.1016/j.jacc.2013.05.045.
19. Baffi CW, Wood L, Winnica D, et al. Metabolic syndrome and the lung.
Chest. 2016;149(6):1525–1534. https://doi.org/10.1016/j.chest.2015.12.
034.
20. Joyce T, Chirino YI, Natalia MT, Jose PC. Renal damage in the metabolic
syndrome (MetSx): Disorders implicated. European Journal of Pharmacol-
ogy. 2018;818:554–568. https://doi.org/10.1016/j.ejphar.2017.11.032.
21. Kim B, Feldman EL: Insulin resistance as a key link for the increased risk of
cognitive impairment in the metabolic syndrome. Experimental and Molec-
ular Medicine. 2015;47(3):e149. https://doi.org/10.1038/emm.2015.3.
100 C. J. Nolan
22. Tobin AM, Ahern T, Rogers S, Collins P, O’Shea D, Kirby B. The der-
matological consequences of obesity. International Journal of Dermatology.
2013;52(8):927–932. https://doi.org/10.1111/j.1365-4632.2012.05624.
x.
23. Simmons RK, Alberti KG, Gale EA, et al. The metabolic syndrome: Useful
concept or clinical tool? Report of a WHO Expert Consultation. Diabetolo-
gia. 2010;53(4):600–605. https://doi.org/10.1007/s00125-009-1620-4.
24. Kakoly NS, Earnest A, Teede HJ, Moran LJ, Joham AE. The impact of
obesity on the incidence of type 2 diabetes among women with polycystic
ovary syndrome. Diabetes Care. 2019;42(4):560–567. https://doi.org/10.
2337/dc18-1738.
25. Tomlinson J, Millward A, Stenhouse E, Pinkney J. Type 2 diabetes and
cardiovascular disease in polycystic ovary syndrome: What are the risks and
can they be reduced? Diabetic Medicine. 2010;27(5):498–515.
26. Ehrmann DA, Barnes RB, RosenfieldRL, Cavaghan MK, Imperial J.Preva-
lence of impaired glucose tolerance and diabetes in women with polycystic
ovary syndrome. Diabetes Care. 1999;22(1):141–146. https://doi.org/10.
2337/diacare.22.1.141.
27. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic
fatty liver disease and risk of incident cardiovascular disease: A meta-
analysis. Journal of Hepatology. 2016;65(3):589–600. https://doi.org/10.
1016/j.jhep.2016.05.013.
28. Zimmet P, Alberti K, Stern N, et al. The Circadian Syndrome: Is the
metabolic syndrome and much more! Journal of Internal Medicine. 2019.
https://doi.org/10.1111/joim.12924.
29. Weaver JU. Classical endocrine diseases causing obesity. Obesity and
Metabolism. 2008;36:212–228. https://doi.org/10.1159/000115367.
30. Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. The
Lancet. 2017;390(10101):1550–1562. https://doi.org/10.1016/s0140-
6736(17)30703-1.
31. Nieman LK. Cushing’s syndrome: Update on signs, symptoms and bio-
chemical screening. European Journal of Endocrinology. 2015;173(4):M33–
M38. https://doi.org/10.1530/eje-15-0464.
32. Naderpoor N, Shorakae S, Joham A, Boyle J, De Courten B, Teede
HJ. Obesity and polycystic ovary syndrome. Minerva Endocrinologica.
2015;40(1):37–51.
33. van der Valk ES, van den Akker ELT, Savas M, et al. A comprehensive
diagnostic approach to detect underlying causes of obesity in adults. Obesity
Reviews. 2019;20(6):795–804. https://doi.org/10.1111/obr.12836.
4 Overview of the Comorbidity … 101
34. Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. The Lancet.
2017;389(10085):2239–2251. https://doi.org/10.1016/s0140-
6736(17)30058-2.
35. Schaefer-Graf U, Napoli A, Nolan CJ. Diabetic Pregnancy Study G.
Diabetes in pregnancy: A new decade of challenges ahead. Diabetologia.
2018;61(5):1012–1021. https://doi.org/10.1007/s00125-018-4545-y.
36. Belenkaia LV, Lazareva LM, Walker W, Lizneva DV, Suturina LV. Criteria,
phenotypes and prevalence of polycystic ovary syndrome. Minerva Gine-
cologica. 2019;71(3):211–223. https://doi.org/10.23736/s0026-4784.19.
04404-6.
37. Wolf WM, Wattick RA, Kinkade ON, Olfert MD. Geographical
prevalence of polycystic ovary syndrome as determined by region and
race/ethnicity. International Journal of Environmental Research and Public
Health. 2018;15(11):2589. https://doi.org/10.3390/ijerph15112589.
38. Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central
obesity in women with polycystic ovary syndrome: A systematic review and
meta-analysis. Human Reproduction Update. 2012;18(6):618–637. https://
doi.org/10.1093/humupd/dms030.
39. El Hayek S, Bitar L, Hamdar LH, Mirza FG, Daoud G. Poly cystic ovar-
ian syndrome: An updated overview. Frontiers in Physiology. 2016;7:124.
https://doi.org/10.3389/fphys.2016.00124.
40. Veltman-Verhulst SM, Boivin J, Eijkemans MJ, Fauser BJ. Emotional dis-
tress is a common risk in women with polycysticovary syndrome: Asystem-
atic review and meta-analysis of 28 studies. Human Reproduction Update.
2012;18(6):638–651. https://doi.org/10.1093/humupd/dms029.
41. Damone AL,Joham AE, LoxtonD, Earnest A,Teede HJ, Moran LJ. Depres-
sion, anxiety and perceived stress in women with and without PCOS: A
community-based study. Psychological Medicine. 2019;49(9):1510–1520.
https://doi.org/10.1017/s0033291718002076.
42. Hart R, Doherty DA. The potential implications of a PCOS diagnosis
on a woman’s long-term health using data linkage. The Journal of Clin-
ical Endocrinology & Metabolism. 2015;100(3):911–919. https://doi.org/
10.1210/jc.2014-3886.
43. O’Brien PD, Hinder LM, Callaghan BC, Feldman EL. Neurological con-
sequences of obesity. The Lancet Neurology. 2017;16(6):465–477. https://
doi.org/10.1016/s1474-4422(17)30084-4.
44. Anstey KJ, Cherbuin N, Budge M, Young J. Body mass index in midlife
and late-life as a risk factor for dementia: A meta-analysis of prospective
102 C. J. Nolan
studies. Obesity Reviews. 2011;12(5):e426–e437. https://doi.org/10.1111/
j.1467-789x.2010.00825.x.
45. Pedditzi E, Peters R, Beckett N. The risk of overweight/obesity in mid-life
and late life for the development of dementia: A systematic review and
meta-analysis of longitudinal studies. Age and Ageing. 2016;45(1):14–21.
https://doi.org/10.1093/ageing/afv151.
46. Qizilbash N, Gregson J, Johnson ME, et al. BMI and risk of dementia
in two million people over two decades: A retrospective cohort study. The
Lancet Diabetes & Endocrinology. 2015;3(6):431–436. https://doi.org/10.
1016/s2213-8587(15)00033-9.
47. Sabia S, Kivimaki M, Shipley MJ, Marmot MG, Singh-Manoux A. Body
mass index over the adult life course and cognition in late midlife: The
Whitehall II cohort study. The American Journal of Clinical Nutrition.
2009;89(2):601–607. https://doi.org/10.3945/ajcn.2008.26482.
48. Mrak RE. Alzheimer-type neuropathological changes in morbidly obese
elderly individuals. Clinical Neuropathology. 2009;28(1):40–45.
49. Taki Y, Kinomura S, Sato K, et al. Relationship between body mass
index and gray matter volume in 1,428 healthy individuals. Obesity.
2008;16(1):119–124. https://doi.org/10.1038/oby.2007.4.
50. Jagust W, Harvey D, Mungas D, Haan M. Central obesity and the aging
brain. Archives of Neurology. 2005;62(10):1545–1548. https://doi.org/10.
1001/archneur.62.10.1545.
51. Pannacciulli N, Del Parigi A, Chen K, Le DS, Reiman EM, Tataranni
PA. Brain abnormalities in human obesity: A voxel-based morphomet-
ric study. Neuroimage. 2006;31(4):1419–1425. https://doi.org/10.1016/
j.neuroimage.2006.01.047.
52. Raji CA, Ho AJ, Parikshak NN, et al. Brain structure and obesity.
Human Brain Mapping. 2010;31(3):353–364. https://doi.org/10.1002/
hbm.20870.
53. Yau PL, Castro MG, Tagani A, Tsui WH, Convit A. Obesity and metabolic
syndrome and functional and structural brain impairments in adoles-
cence. Pediatrics. 2012;130(4):e856–864. https://doi.org/10.1542/peds.
2012-0324.
54. Alosco ML, Stanek KM, Galioto R, et al. Body mass index and brain
structure in healthy children and adolescents. International Journal of Neu-
roscience. 2014;124(1):49–55. https://doi.org/10.3109/00207454.2013.
817408.
4 Overview of the Comorbidity … 103
55. Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in
Alzheimer’s disease. The Lancet Neurology. 2015;14(4):388–405. https://
doi.org/10.1016/s1474-4422(15)70016-5.
56. Polsek D, GildehN, CashD, et al. Obstructive sleepapnoea andAlzheimer’s
disease: In search of sharedpathomechanisms. Neuroscience& Biobehavioral
Reviews. 2018;86:142–149. https://doi.org/10.1016/j.neubiorev.2017.12.
004.
57. Alfaro FJ, Gavrieli A, Saade-Lemus P, Lioutas VA, Upadhyay J, Novak V.
White matter microstructure and cognitive decline in metabolic syndrome:
A review of diffusion tensor imaging. Metabolism. 2018;78:52–68. https://
doi.org/10.1016/j.metabol.2017.08.009.
58. Salameh TS, Rhea EM, Banks WA, Hanson AJ. Insulin resistance, dys-
lipidemia, and apolipoprotein E interactions as mechanisms in cognitive
impairment and Alzheimer’s disease. Experimental Biology and Medicine.
2016;241(15):1676–1683. https://doi.org/10.1177/1535370216660770.
59. Dewan NA, Nieto FJ, Somers VK. Intermittent hypoxemia and OSA:
Implications for comorbidities. Chest. 2015;147(1):266–274. https://doi.
org/10.1378/chest.14-0500.
60. Clark IA, Alleva LM, Vissel B. The roles of TNF in brain dysfunction and
disease. Pharmacology andTherapeutics. 2010;128(3):519–548. https://doi.
org/10.1016/j.pharmthera.2010.08.007.
61. Thorp AA, Schlaich MP. Relevance of sympathetic nervous system acti-
vation in obesity and metabolic syndrome. Journal of Diabetes Research.
2015;2015:341583. https://doi.org/10.1155/2015/341583.
62. Balasubramanian P, Hall D, Subramanian M. Sympathetic nervous system
as a target for aging and obesity-related cardiovascular diseases. Geroscience.
2019;41(1):13–24. https://doi.org/10.1007/s11357-018-0048-5.
63. Canale MP, Manca di Villahermosa S, Martino G, et al. Obesity-related
metabolic syndrome: Mechanisms of sympathetic overactivity. Interna-
tional Journal of Endocrinology. 2013;2013:865965. https://doi.org/10.
1155/2013/865965.
64. Callaghan BC, Xia R, Banerjee M, et al. Metabolic syndrome components
are associated with symptomatic polyneuropathy independent of glycemic
status. Diabetes Care. 2016;39(5):801–807. https://doi.org/10.2337/dc16-
0081.
65. Karelis AD. Metabolically healthy but obese individuals. The
Lancet. 2008;372(9646):1281–1283. https://doi.org/10.1016/s0140-
6736(08)61531-7.
104 C. J. Nolan
66. Hinnouho GM, Czernichow S, Dugravot A, et al. Metabolically healthy
obesity and the risk of cardiovascular disease and type 2 diabetes: The
Whitehall II cohort study. European Heart Journal. 2015;36(9):551–559.
https://doi.org/10.1093/eurheartj/ehu123.
67. Thomsen M, Nordestgaard BG. Myocardial infarction and ischemic heart
disease in overweight and obesity with and without metabolic syndrome.
JAMA Internal Medicine. 2014;174(1):15–22. https://doi.org/10.1001/
jamainternmed.2013.10522.
68. Arnlov J, Ingelsson E, Sundstrom J, Lind L. Impact of body mass index and
the metabolic syndrome on the risk of cardiovascular disease and death in
middle-aged men. Circulation. 2010;121(2):230–236. https://doi.org/10.
1161/circulationaha.109.887521.
69. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure.
New England Journal of Medicine. 2002;347(5):305–313. https://doi.org/
10.1056/nejmoa020245.
70. Alpert MA, Lavie CJ, Agrawal H, Aggarwal KB, Kumar SA. Obesity and
heart failure: Epidemiology, pathophysiology, clinical manifestations, and
management. Translational Research. 2014;164(4):345–356. https://doi.
org/10.1016/j.trsl.2014.04.010.
71. Baena-Diez JM, Byram AO, Grau M, et al. Obesity is an independent risk
factor for heart failure: Zona Franca cohort study. Clinical Investigations.
2010;33(12):760–764. https://doi.org/10.1002/clc.20837.
72. Alexander JK, Dennis EW, Smith WG, Amad KH, Duncan WC, Austin
RC. Blood volume, cardiac output, and distribution of systemic blood flow
in extreme obesity. Cardiovascular Research Center Bulletin. 1962;1:39–44.
73. Lyons OD, BradleyTD. Heart failure and sleep apnea. Canadian Journal of
Cardiology. 2015;31(7):898–908. https://doi.org/10.1016/j.cjca.2015.04.
017.
74. Holt A, Bjerre J, Zareini B, et al. Sleep apnea, the risk of devel-
oping heart failure, and potential benefits of continuous positive air-
way pressure (CPAP) therapy. Journal of the American Heart Association.
2018;7(13):e008684. https://doi.org/10.1161/jaha.118.008684.
75. Grassi G, Seravalle G, Quarti-Trevano F, et al. Excessive sympathetic activa-
tion in heart failure with obesity and metabolic syndrome: Characteristics
and mechanisms. Hypertension. 2007;49(3):535–541. https://doi.org/10.
1161/01.hyp.0000255983.32896.b9.
4 Overview of the Comorbidity … 105
76. Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM,
McAlister FA. Body mass index and mortality in heart failure: A meta-
analysis. American Heart Journal. 2008;156(1):13–22. https://doi.org/10.
1016/j.ahj.2008.02.014.
77. Poulain M, Doucet M,Major GC, et al.The effect of obesity on chronic res-
piratory diseases: Pathophysiology and therapeutic strategies. CMAJ: Cana-
dian MedicalAssociation Journal. 2006;174(9):1293–1299. https://doi.org/
10.1503/cmaj.051299.
78. Melo LC, Silva MA, Calles AC. Obesity and lung function: A system-
atic review. Einstein (Sao Paulo). 2014;12(1):120–125. https://doi.org/10.
1590/s1679-45082014rw2691.
79. Beuther DA, Sutherland ER. Overweight, obesity, and incident asthma:
A meta-analysis of prospective epidemiologic studies. American Journal of
Respiratory and Critical Care Medicine. 2007;175(7):661–666. https://doi.
org/10.1164/rccm.200611-1717oc.
80. Peters U, Dixon AE, Forno E. Obesity and asthma. Journal of Allergy and
Clinical Immunology. 2018;141(4):1169–1179. https://doi.org/10.1016/j.
jaci.2018.02.004.
81. Lambert AA, Putcha N, Drummond MB, et al. Obesity is associated with
increased morbidity in moderate to severe COPD. Chest. 2017;151(1):68–
77. https://doi.org/10.1016/j.chest.2016.08.1432.
82. Divo MJ, Cabrera C, Casanova C, et al. Comorbidity distribution, clinical
expression and survival in COPD patients with different body mass index.
Chronic Obstructive Pulmonary Diseases. 2014;1(2):229–238. https://doi.
org/10.15326/jcopdf.1.2.2014.0117.
83. Soylu AC, Levent E, Sariman N, Yurtlu S, Alparslan S, Saygi A. Obstructive
sleep apnea syndrome and anthropometric obesity indexes. Sleep Breath.
2012;16(4):1151–1158. https://doi.org/10.1007/s11325-011-0623-9.
84. van der Spuy I, Zhao G, Karunanayake C, Pahwa P. Predictors of
sleep apnea in the Canadian population. Canadian Respiratory Journal.
2018;2018:6349790. https://doi.org/10.1155/2018/6349790.
85. Punjabi NM. The epidemiology of adult obstructive sleep apnea. Proceed-
ings of the American Thoracic Society. 2008;5(2):136–143. https://doi.org/
10.1513/pats.200709-155mg.
86. Luyster FS, Kip KE, Buysse DJ, Aiyer AN, Reis SE, Strollo PJ, Jr. Tradi-
tional and nontraditional cardiovascular risk factors in comorbid insom-
nia and sleep apnea. Sleep. 2014;37(3):593–600. https://doi.org/10.5665/
sleep.3506.
106 C. J. Nolan
87. Wang Y, Li C, Feng L, Feng J, Cao J, Chen B. Prevalence of hypertension
and circadian blood pressure variations in patients with obstructive sleep
apnoea-hypopnoea syndrome. Journal of International Medical Research.
2014;42(3):773–780. https://doi.org/10.1177/0300060513516756.
88. Rezaeitalab F, Moharrari F, Saberi S, Asadpour H, Rezaeetalab F. The cor-
relation of anxiety and depression with obstructive sleep apnea syndrome.
Journal of Research in Medical Sciences. 2014;19(3):205–210.
89. Gottlieb DJ, Whitney CW, Bonekat WH, et al. Relation of sleepiness to res-
piratory disturbance index: The sleep heart health study. American Journal
of Respiratory and Critical Care Medicine. 1999;159(2):502–507. https://
doi.org/10.1164/ajrccm.159.2.9804051.
90. Mokhlesi B. Obesity hypoventilation syndrome: A state-of-the-art review.
Respiratory Care. 2010;55(10):1347–1362; discussion 1363–1365.
91. Pierce AM, Brown LK. Obesity hypoventilation syndrome: Current
theories of pathogenesis. Current Opinion in Pulmonary Medicine.
2015;21(6):557–562. https://doi.org/10.1097/mcp.0000000000000210.
92. Chang P, Friedenberg F. Obesity and GERD. Gastroenterology Clinics of
North America. 2014;43(1):161–173. https://doi.org/10.1016/j.gtc.2013.
11.009.
93. El-Serag H. The association between obesity and GERD: A review of the
epidemiological evidence. DigestiveDiseases andSciences. 2008;53(9):2307–
2312. https://doi.org/10.1007/s10620-008-0413-9.
94. Stein DJ, El-Serag HB, Kuczynski J, Kramer JR, Sampliner RE. The associ-
ation of body mass index with Barrett’s oesophagus. Alimentary Pharmacol-
ogy and Therapeutics. 2005;22(10):1005–1010. https://doi.org/10.1111/j.
1365-2036.2005.02674.x.
95. Hoyo C, Cook MB, Kamangar F, et al. Body mass index in relation to
oesophageal and oesophagogastric junction adenocarcinomas: A pooled
analysis from the International BEACON Consortium. International Jour-
nal of Epidemiology. 2012;41(6):1706–1718. https://doi.org/10.1093/ije/
dys176.
96. Stampfer MJ, Maclure KM, Colditz GA, Manson JE, Willett WC. Risk of
symptomatic gallstones in women with severe obesity. The American Journal
of Clinical Nutrition. 1992;55(3):652–658. https://doi.org/10.1093/ajcn/
55.3.652.
97. Bonfrate L, Wang DQ, Garruti G, Portincasa P. Obesity and the risk and
prognosis of gallstone disease and pancreatitis. Best Practice & Research Clin-
ical Gastroenterology. 2014;28(4):623–635. https://doi.org/10.1016/j.bpg.
2014.07.013.
4 Overview of the Comorbidity … 107
98. Cruz-Monserrate Z, Conwell DL, Krishna SG. The impact of obesity on
gallstone disease, acute pancreatitis, and pancreatic cancer. Gastroenterology
Clinics. 2016;45(4):625–637. https://doi.org/10.1016/j.gtc.2016.07.010.
99. Sadr-Azodi O,Orsini N, Andren-SandbergA, WolkA. Abdominaland total
adiposity and the risk of acute pancreatitis: A population-based prospective
cohort study. American Journal of Gastroenterology. 2013;108(1):133–139.
https://doi.org/10.1038/ajg.2012.381.
100. Krishna SG, Hinton A, Oza V, et al. Morbid obesity is associated with
adverse clinical outcomes in acute pancreatitis: A propensity-matched
study. The American Journal of Gastroenterology. 2015;110(11):1608–1619.
https://doi.org/10.1038/ajg.2015.343.
101. Martinez J, Johnson CD, Sanchez-Paya J, de Madaria E, Robles-Diaz
G, Perez-Mateo M. Obesity is a definitive risk factor of severity and
mortality in acute pancreatitis: An updated meta-analysis. Pancreatology.
2006;6(3):206–209. https://doi.org/10.1159/000092104.
102. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty
liver disease and nonalcoholic steatohepatitis among a largely middle-
aged population utilizing ultrasound and liver biopsy: A prospective study.
Gastroenterology. 2011;140(1):124–131. https://doi.org/10.1053/j.gastro.
2010.09.038.
103. WongVW, Chitturi S, Wong GL, Yu J, Chan HL, Farrell GC. Pathogenesis
and novel treatment options for non-alcoholic steatohepatitis. The Lancet
Gastroenterology & Hepatology. 2016;1(1):56–67. https://doi.org/10.1016/
s2468-1253(16)30011-5.
104. Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of
type 2 diabetes mellitus and associated chronic kidney disease. Nature
Reviews Nephrology. 2016;12(2):73–81. https://doi.org/10.1038/nrneph.
2015.173.
105. Kovesdy CP, Furth SL, Zoccali C, World Kidney Day Steering Committee.
Obesity and kidney disease: Hidden consequences of the epidemic. Kidney
International. 2017;91(2):260–262. https://doi.org/10.1016/j.kint.2016.
10.019.
106. Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association between
obesity and kidney disease: A systematic review and meta-analysis. Kidney
International. 2008;73(1):19–33. https://doi.org/10.1038/sj.ki.5002586.
107. George MD, Baker JF.The obesity epidemic and consequences for rheuma-
toid arthritis care. Current Rheumatology Reports. 2016;18(1):6. https://doi.
org/10.1007/s11926-015-0550-z.
108 C. J. Nolan
108. Bliddal H,Leeds AR,Christensen R.Osteoarthritis, obesityand weightloss:
Evidence, hypotheses and horizons—A scoping review. Obesity Reviews.
2014;15(7):578–586. https://doi.org/10.1111/obr.12173.
109. Wannamethee SG, Atkins JL. Muscle loss and obesity: The health implica-
tions of sarcopenia and sarcopenic obesity. Proceedings of the Nutrition Soci-
ety. 2015;74(4):405–412. https://doi.org/10.1017/s002966511500169x.
110. Li X, Gong X, Jiang W. Abdominal obesity and risk of hip frac-
ture: A meta-analysis of prospective studies. Osteoporosis International.
2017;28(10):2747–2757. https://doi.org/10.1007/s00198-017-4142-9.
111. Cicuttini FM, Wluka AE. Not just loading and age: The dynamics of
osteoarthritis, obesity and inflammation. Medical Journal of Australia.
2016;204(2):47. https://doi.org/10.5694/mja15.01069.
112. Felson DT, Anderson JJ, Naimark A, Walker AM, Meenan RF. Obesity and
knee osteoarthritis: The Framingham study. Annals of Internal Medicine.
1988;109(1):18–24. https://doi.org/10.7326/0003-4819-109-1-18.
113. Godziuk K, Prado CM, Woodhouse LJ, Forhan M. The impact of sar-
copenic obesityon kneeand hiposteoarthritis: A scoping review. BMC Mus-
culoskeletal Disorders. 2018;19(1):271. https://doi.org/10.1186/s12891-
018-2175-7.
114. Batsis JA, Zbehlik AJ, Barre LK, Bynum JP, Pidgeon D, Bartels SJ.
Impact of obesity on disability, function, and physical activity: Data
from the osteoarthritis initiative. Scandinavian Journal of Rheumatology.
2015;44(6):495–502. https://doi.org/10.3109/03009742.2015.1021376.
115. Qin B, Yang M, Fu H, et al. Body mass index and the risk of rheumatoid
arthritis: A systematic review and dose-response meta-analysis. Arthritis
Research & Therapy. 2015;17(1):86. https://doi.org/10.1186/s13075-015-
0601-x.
116. Kaze AD, Rosen HN, Paik JM. A meta-analysis of the association between
body mass index and risk of vertebral fracture. Osteoporosis International.
2018;29(1):31–39. https://doi.org/10.1007/s00198-017-4294-7.
117. Scott D, Chandrasekara SD, Laslett LL, Cicuttini F, Ebeling PR, Jones G.
Associations of sarcopenic obesity anddynapenic obesity withbone mineral
density andincident fracturesover 5–10years incommunity-dwelling older
adults. Calcified Tissue International. 2016;99(1):30–42. https://doi.org/
10.1007/s00223-016-0123-9.
118. Scott D, Seibel M, Cumming R, et al. Sarcopenic obesity and its tempo-
ral associations with changes in bone mineral density, incident falls, and